A synthetic inhibitor of factor Xa, DX-9065a, reduces proliferation of vascular smooth muscle cells in vivo in rats

Thrombosis Research

Volumn 98, Issue 2, 2000, Pages 175-185

  Kaiser, Brigitte ^a   Paintz, Manfred ^a   Scholz, Olaf ^a   Kunitada, Satoshi ^b   Fareed, Jawed ^c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b DAIICHI SANKYO CO   (Japan)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

DX 9065a; Experimental model; Factor Xa; Vascular smooth muscle cell proliferation

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; BLOOD CLOTTING FACTOR 10A INHIBITOR; BROXURIDINE; HEMATOXYLIN; THYMIDINE; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; CELL PROLIFERATION; COMMON CAROTID ARTERY; CONTINUOUS INFUSION; CONTROLLED STUDY; ENDOTHELIUM LESION; FEMALE; INTIMA; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RAT; RESTENOSIS; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTICOAGULANTS; ARTERIOSCLEROSIS; CAROTID ARTERY INJURIES; CAROTID ARTERY, COMMON; CELL DIVISION; DISEASE MODELS, ANIMAL; FACTOR XA; FEMALE; MALE; MUSCLE, SMOOTH, VASCULAR; NAPHTHALENES; PROPIONIC ACIDS; RATS; RATS, WISTAR; RECURRENCE;

EID: 0034655172     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(99)00213-3     Document Type: Article

References (34)

1. Altieri D.C., Edgington T.S. Identification of effector cell protease receptor-1. A leukocyte-distributed receptor for the serine protease factor Xa J Immunol. 145:1990;246-253.
2. Altieri D.C. Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem. 269:1994;3139-3142.
3. Altieri D.C. Xa receptor EPR-1. FASEB J. 9:1995;860-865.
4. Bouchard B.A., Catcher C.S., Thrash B.R., Adida C., Tracy P.B. Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation. J Biol Chem. 272:1997;9244-9251.
5. Bono F., Hérault J.P., Avril C., Schaeffer P., Lormeau J.C., Herbert J.M. Human umbilical vein endothelial cells express high affinity receptors for factor Xa. J Cell Physiol. 172:1997;36-43.
6. Nicholson A.C., Nachman R.L., Altieri D.C., Summers B.D., Ruf W., Edgington T.S., Hajjar D.P. Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa. J Biol Chem. 271:1996;28407-28413.
7. Ambrosini G., Altieri D.C. Molecular dissection of effector cell protease receptor-1 recognition of factor Xa. Assignment of critical residues involved in antibody reactivity and ligand binding. J Biol Chem. 271:1996;1243-1248.
8. Cirino G., Cicala C., Bucci M., Sorrentino L., Ambrosini G., DeDominicis G., Altieri D.C. Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. J Clin Invest. 99:1997;2446-2451.
9. Schaeffer P., Mares A.M., Dol F., Bono F., Herbert J.M. Coagulation factor Xa induces endothelium-dependent relaxations in rat aorta. Circ Res. 81:1997;824-828.
10. Ko F.N., Yang Y.C., Huang S.C., Ou J.T. Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat. J Clin Invest. 98:1996;1493-1501.
11. Herbert J.M., Bono F., Hérault J.P., Avril C., Dol F., Mares A.M., Schaeffer P. Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo. J Clin Invest. 101:1998;993-1000.
12. Gasic G.P., Arenas C.P., Gasic T.B., Gasic G.J. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA. 89:1992;2317-2320.
13. Ragosta M., Gimple L.W., Gertz S.D., Dunwiddie C.T., Vlasuk G.P., Haber H.L., Powers E.R., Roberts W.C., Sarembock I.J. Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 89:1994;1262-1271.
14. Schwartz R.S., Holder D.J., Holmes D.R., Veinot J.P., Camrud A.R., Jorgenson M.A., Johnson R.G. Neointimal thickening after severe coronary artery injury is limited by short-term administration of a factor Xa inhibitor. Results in a porcine model. Circulation. 93:1996;1542-1548.
15. Hara T., Yokoyama A., Ishihara H., Yokoyama Y., Nagakara T., Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost. 71:1994;314-319.
16. Yokoyama T., Kelly A.B., Marzec U.M., Hanson S.R., Kunitada S., Harker L.A. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation. 92:1995;485-491.
17. Herbert J.M., Bernat A., Dol F., Hérault J.P., Crépon B., Lormeau J.C. DX 9065A, a novel, synthetic, selective and orally active inhibitor of factor Xa. In vitro and in vivo studies J Pharmacol Exp Ther. 276:1996;1030-1038.
18. Kim D.I., Kambayashi J., Shibuya T., Sakon M., Kawasaki T. In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft. J Atheroscler Thromb. 2:1996;110-116.
19. Yamazaki M., Asakura H., Aoshima K., Saito M., Jokaji H., Uotani C., Kumabashiri I., Morishita E., Ikeda T., Matsuda T. Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats. Semin Thromb Hemost. 22:1996;255-259.
20. Morishima Y., Tanabe K., Terada Y., Hara T., Kunitada S. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor. Comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants Thromb Haemost. 78:1997;1366-1371.
21. Yamashita T., Tsuji T., Matsuoka A., Giddings J.C., Yamamoto J. The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric vessels. Thromb Res. 85:1997;45-51.
22. Kaiser B., Jeske W., Walenga J.M., Kunitada S., Fareed J. Inactivation of factor Xa by the synthetic inhibitor DX-9065a causes strong anticoagulant and antiplatelet actions in human blood. Blood Coagul Fibrinol. 10:1999;495-501.
23. Bradford M.M. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
24. Lille S., Daum G., Clowes M., Clowes A. The regulation of p42/p44 mitogen-activated protein kinases in the injured rat carotid artery. J Surg Res. 70:1997;178-186.
25. Benzakour O., Kanthou C. Cellular and molecular events in atherogenesis. Basis for pharmacological and gene therapy approaches to restenosis Cell Pharmacol. 3:1996;7-22.
26. Kanthou C., Benzakour O. Cellular effects of thrombin and their signalling pathways. Cell Pharmacol. 2:1995;293-302.
27. Herault J.P., Bono F., Avril C., Schaeffer P., Herbert J.M. Activation of human vascular endothelial cells by factor Xa. Effect of specific inhibitors Biochem Pharmacol. 57:1999;603-610.
28. Weber A.A., Schrör K. The significance of platelet-derived growth factors for proliferation of vascular smooth muscle cells. Platelets. 10:1999;77-96.
29. Johnson G.J., Griggs T.R., Badimon L. The utility of animal models in the preclinical study of interventions to prevent human coronary artery restenosis. Analysis and recommendations Thromb Haemost. 81:1999;835-843.
30. Kaiser B., Paintz M., Glusa E., Kunitada S., Fareed J. Antiproliferative action of factor Xa inhibitors in a rat model of chronic restenosis. Thromb Haemost. Suppl:1999;144.
31. Abendschein D.R., Recchia D., Meng Y.Y., Oltrona L., Wickline S.A., Eisenberg P.R. Inhibition of thrombin attenuates stenosis after arterial injury in minipigs. J Am Coll Cardiol. 28:1996;1849-1855.
32. McNamara C.A., Sarembock I.J., Bachhuber B.G., Stouffer G.A., Ragosta M., Barry W., Gimple L.W., Powers E.R., Owens G.K. Thrombin and vascular smooth muscle cell proliferation. Implications for atherosclerosis and restenosis Semin Thromb Hemost. 22:1996;139-144.
33. Nakata M., Kanekura S., Maruyama I. DX-9065a, an Xa inhibitor, inhibits prothrombin-induced A549 lung adenocarcinoma cell proliferation. Cancer Lett. 122:1998;127-133.
34. Ghigliotti G., Waissbluth A.R., Speidel C., Abendschein D.R., Eisenberg P.R. Prolonged activation of prothrombin on the vascular wall after arterial injury. Arterioscler Thromb Vasc Biol. 18:1998;250-257.